Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

NewAmsterdam Pharma (NAMS) EBT Margin (2023 - 2025)

NewAmsterdam Pharma (NAMS) has disclosed EBT Margin for 3 consecutive years, with 234134.38% as the latest value for Q4 2025.

  • Quarterly EBT Margin fell 23341266.0% to 234134.38% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 905.74% through Dec 2025, down 37549.0% year-over-year, with the annual reading at 905.74% for FY2025, 37549.0% down from the prior year.
  • EBT Margin hit 234134.38% in Q4 2025 for NewAmsterdam Pharma, down from 20691.09% in the prior quarter.
  • In the past five years, EBT Margin ranged from a high of 57.19% in Q3 2024 to a low of 234134.38% in Q4 2025.
  • Historically, EBT Margin has averaged 22992.24% across 3 years, with a median of 1657.1% in 2023.
  • Biggest five-year swings in EBT Margin: surged 543869bps in 2024 and later plummeted -23341266bps in 2025.
  • Year by year, EBT Margin stood at 6160.4% in 2023, then skyrocketed by 88bps to 721.71% in 2024, then tumbled by -32342bps to 234134.38% in 2025.
  • Business Quant data shows EBT Margin for NAMS at 234134.38% in Q4 2025, 20691.09% in Q3 2025, and 90.7% in Q2 2025.